Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it.See plans →

Viyash Scientific acquires Bio For Life in Italy

PRIVATEAug 16, 2026about 2 hours ago

Acquiring Company

Viyash Scientific

Acquired Company

Bio For Life

ItalyBiotechnologyHealth CareAnimal FeedPetVeterinary

Description

Viyash Scientific has executed a Share Purchase Agreement to acquire Bio For Life, a company based in Italy that specializes in companion animal products. The acquisition is expected to bolster Viyash’s presence in the European companion animal market. The deal was finalized on July 21, 2026, with an expected closing in September 2026. Integration and product registration processes are predicted to take 18-24 months, with anticipated significant revenue contributions thereafter.

Company Information

Company

Viyash Scientific

About

Viyash Scientific is an animal health and pharmaceutical company primarily focused on the production and distribution of formulations and active pharmaceutical ingredients (APIs). The company has been experiencing significant growth and profitability in recent quarters. They aim to expand their presence in international markets, particularly in Europe. Viyash is recognized for its innovative solutions in the animal health sector.

Don't miss Viyash Scientific's next move

Get an email the moment Viyash Scientific makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Viyash Scientific's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Bio For Life?

Bio For Life was acquired by Viyash Scientific. The deal was reported on August 16, 2026. Viyash Scientific is an animal health and pharmaceutical company primarily focused on the production and distribution of formulations and active pharmaceutical ingredients (APIs). Viyash Scientific is privately held.

When did Viyash Scientific acquire Bio For Life?

Viyash Scientific's acquisition of Bio For Life was reported on August 16, 2026. Viyash Scientific has executed a Share Purchase Agreement to acquire Bio For Life, a company based in Italy that specializes in companion animal products. The acquisition is expected to bolster Viyash’s presence in the European companion animal market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Bio For Life do?

Bio For Life is a company focused on the companion animal segment, supplying a wide range of veterinary products. The company has a portfolio of approximately 85-90 products that cater to the needs of pet owners and veterinarians. It is privately held, operating in Biotechnology, and is based in Italy.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.